MARA Ratings reflect the evidence and payer context available as of the stated date. Where material new evidence or payer decisions emerge, MARA may issue a rating action under the Rating Actions & Surveillance Policy.
For market-specific extensions or updated cut dates, request a revised assessment.
The Full MARA Assessment provides full 10-domain scoring, weighted determinants, benchmarking against comparable assets, and historical context calibrated to observed HTA outcomes.
This assessment positions the asset relative to reimbursement thresholds observed across major HTA bodies. It distinguishes structural drivers of reimbursement risk from variables that are typically sensitive to evidence maturity or price expectations.
The Full MARA Assessment provides weighted scoring across all 10 domains and benchmarks this positioning against historical reimbursement outcomes for comparable evidence profiles.
Below is a snapshot of domains that materially influence the MARA Rating. The Full MARA Assessment provides complete 10-domain scoring and the evidence-linked rationale for each domain outcome.
Clinical effectiveness
Cost effectiveness
Quality of life
The Full MARA Reimbursement Risk Assessment expands this analysis with weighted scoring, benchmarking depth, and ranking versus hundreds of comparable assets.
This asset is benchmarked against therapeutic-area comparators and a historical dataset of previously assessed products. MARA calibrates rating bands against observed reimbursement outcomes across major HTA bodies.
Designed to support governance and diligence before major commitments in pricing, evidence generation, partnering, or launch planning.
The MARA Rating provides a standardized, committee-reviewed assessment of the reimbursement risk associated with this drug–indication pair, calibrated against historical HTA and payer outcomes across the US, EU4, UK, and Japan.
The licensed report includes structured scoring across 10 payer-relevant domains, evidence-linked rationale, benchmarking against comparable assets, and identification of variables that may influence rating migration.
The complimentary summary provides the rating band, market access score, confidence level, and high-level context. Detailed domain scoring, benchmarking analysis, and full rationale are available in the licensed report.
This rating is subject to defined surveillance under the Rating Actions & Surveillance Policy. Where material new evidence, payer decisions, or policy changes occur, MARA may issue a rating action (affirmation, upgrade, downgrade, or under review) with an as-of date and rationale.
This aligns every report page with your governance system.
MARA Rating is an independent analytical opinion intended for professional use in market access, HTA, and investment contexts. It does not constitute medical, legal, or investment advice.
The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. All opinions, analyses, and recommendations are statements of opinion, not statements of fact, and are supplied “as-is” without warranty of any kind, express or implied, including accuracy, completeness, or fitness for any particular purpose. Users assume full responsibility for their decisions and any consequences thereof. MARA Rating Company expressly disclaims all liability for any outcomes arising from the use of, or actions taken based on, this report. Report may contain public sector information licensed under the Open Government Licence v3.0.© Crown copyright 2025 and others. All brand names are the property of their respective owners. For reimbursement & HTA professionals only – Not for patients, prescribers or the general public. Rights & Display. © MARA Rating Company AG. Viewing permitted. Reproduction, reprinting, redistribution, scraping, or public display of any MARA rating, badge, letter grade, chart, or the “Primary line” in marketing, IR, PR, sales, paid media, conference materials, or websites is prohibited without a valid MARA Display License. Non-licensees may link to this page/report but may not copy, repost, or restyle our content. Use must include the as-of date, our one-line explainer, and no edits to wording or artwork. No composite marks (do not combine the MARA badge with other logos/seals). No implication of MARA’s endorsement of efficacy, safety, price, or any transaction. “MARA”, “MARA Rating”, and the MARA badge are trademarks of MARA Rating Company AG. academic excerpt: up to 50 words of text (no badge/graphics) may be quoted with clear attribution and link. No commercial use. Misuse or corrections: contact sales@mararating.com.